WO2021150178A1

WO2021150178A1 - Pharmaceutical compositions comprising ibuprofen, pseudoephedrine and ascorbic acid

Info

Publication number: WO2021150178A1
Application number: PCT/TR2020/050049
Authority: WO
Inventors: Abdulhaluk SANCAK; Ayşe Figen ONUK GÖREN; Başak ACAR KARAKÖY; Hakan Gürpinar; Koray YILMAZ; Ayla SEYİDOĞLU KÖKSAL; Elif BENİM
Original assignee: Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş.
Priority date: 2020-01-23
Filing date: 2020-01-23
Publication date: 2021-07-29

Abstract

The present invention relates to the preparation of pharmaceutical compositions in the form of bilayer tablet comprising ibuprofen, pseudoephedrine and ascorbic acid; and also relevant excipients, having an improved formulation design by using bilayer tablet manufacturing method. First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of ibuprofen is between 3:10 to 9:10 (w/w) and the weight ratio of pseudoephedrine is between 1:25 to 5:25 (w/w) by the weight of the first layer; second layer comprises ascorbic acid and relevant excipients, wherein the weight ratio of ascorbic acid is between 7:10 to 10:10 (w/w) by the weight of the second layer.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING IBUPROFEN, PSEUDOEPHEDRINE AND ASCORBIC ACID

Field of invention

The present invention relates to the preparation of pharmaceutical compositions comprising ibuprofen, pseudoephedrine and ascorbic acid; and also relevant excipients, having an improved formulation design by using bilayer tablet manufacturing method.

Background of the invention

Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation and high temperature in body. One of the main types of NS AID is ibuprofen that is well-known anti-inflammatory drug, found in 1960s.

Ibuprofen reference product, (Brufen) has been in the market for 50 years. Many different dosage forms are available such as capsules, tablets, or powder in the market. Ibuprofen is used to treat fever and pain from arthritis, headache, dental pain, menstrual cramps, and muscular aches. It works by reducing inflammation. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. ibuprofen, has a powdery white appearance, chemical name is 2-(4-isobutylphenyl) propionic acid, having a molecular weight of 206.28 g/mol. (Figure 1)

Figure 1: Ibuprofen

Pseudoephedrine has characteristics of sympathomimetic drug, also it is used as a nasal/sinus decongestant, as a stimulant, or as a wakefulness-promoting agent in higher doses.

The salts pseudoephedrine hydrochloride are found in many pharmaceutical products, either as a single ingredient or (more commonly) in a combination with one or more additional active ingredients such as antihistamines, guaifenesin, dextromethorphan, paracetamol (acetaminophen) or an NSAID (such as ibuprofen).

Pseudoephedrine is a stimulant, but it is often used as a decongestant. It helps to reduce tissue hyperemia, edema, and nasal congestion commonly associated with colds or allergies, also to icrease the drainage of sinus secretions. It is indicated for the treatment of nasal congestion, sinus congestion and Eustachian tube congestion and vasomotor rhinitis, allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Pseudoephedrine, has crystal form, chemical name is (lS,2S)-2-(methylamino)-l- phenylpropan-l-ol, having a molecular weight of 165,23 g/mol. (Figure 2)

Figure 2: Pseudoephedrine

Ascorbic Acid (Vitamin C) that is also known ascorbate, is a natural water-soluble vitamin. Ascorbic acid has a potent reducing and antioxidant agent that for in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen in fibrous tissue, teeth, bones, connective tissue, skin, and capillaries.

Ascorbic Acid is white to slightly yellowish crystalline powder, practically odorless, with a strong acidic taste. Its chemical name is (5R)-5-[(lS)-l,2-Dihydroxyethyl]-3,4-dihydroxy- 2(5H)-furanone, having a molecular weight of 176,12 g/mol. (Figure 3)

Figure 3: Ascorbic Acid

EP0674527 relates to a pharmaceutical composition comprising ibuprofen, flurbiprofen or ketoprofen and decongestant, expectorant or antitussive for relieving cold or influenza symptoms. WO 2005/063219 relates to ibuprofen-containing soft gelatin capsules, pharmaceutical compositions of a substantially clear ibuprofen solution, and process for their manufacture. It also relates to pharmaceutical compositions of substantially clear solutions containing ibuprofen and pseudoephedrine and use of such compositions for treatment of common cold and flu-like symptoms. JP2007023026 relates to an oral pharmaceutical composition, useful for treating fever, pain, migraine, inflammation and cold, comprises preset amount of ibuprofen and magnesium oxide.

EP1696874 relates to effervescent preparations containing pseudoephedrine, useful e.g. for treating influenza or colds, having composition inhibiting drug accumulation to reduce risk of side-effects.

US4990535 relates to a pharmaceutical composition for use in the treatment of cough/cold symptoms comprising ibuprofen, pseudoephedrine and loratadine. Summary of the invention

The present invention relates to preparation of pharmaceutical composition comprising ibuprofen, pseudoephedrine and ascorbic acid and also relevant excipients, wherein process including bilayer tablet manufacturing method.

The present invention provides a pharmaceutical composition comprising ibuprofen, pseudoephedrine and ascorbic acid, wherein the weight ratio of ibuprofen and weight of first layer is between 3:10 to 9:10 (w/w), wherein the weight ratio of pseudoephedrine and weight of first layer is between 1:25 to 1:5 (w/w), wherein the weight ratio of ascorbic acid and weight of second layer is between 7:10 to 1:1 (w/w) in a bilayer tablet.

Detailed Description of the invention

The invention provides a pharmaceutical composition in the form of bilayer tablet comprising a) First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of ibuprofen is between 3: 10 to 9: 10 (w/w) by the weight of the first layer, b) First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of pseudoephedrine is between 1:25 to 5:25 (w/w) by the weight of the first layer, c) Second layer comprises ascorbic acid and relevant excipients, wherein the weight ratio of ascorbic acid is between 7:10 to 10:10 (w/w) by the weight of the second layer.

The invention provides a pharmaceutical composition in the form of bilayer tablet comprising a) First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of ibuprofen is between 5:10 to 7:10 (w/w) by the weight of the first layer, b) First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of pseudoephedrine is between 2:25 to 4:25 (w/w) by the weight of the first layer, c) Second layer comprises ascorbic acid and relevant excipients, wherein the weight ratio of ascorbic acid is between 7:10 to 9:10 (w/w) by the weight of the second layer.

In this invention, first portion mixture and the second portion mixture is compressed as bilayer tablet, then final product coated.

Pseudoephedrine and ascorbic acid are chemically incompatible active substances each other. Therefore, formulation design is made taking into account this incompatibility. To provide optimum tablet composition comprising active ingredients which are ibuprofen, pseudoephedrine and ascorbic acid, formulation is designed by bilayer tablet manufacturing method.

Bilayer tablet composition comprising active ingredients which are ibuprofen, pseudoephedrine and ascorbic acid, is used for relieving nasal congestion, headache, fever, body pains and other types of pain seen in the progress of flue, cold or sinusitis.

A special PVA-based coating material is used in the coating process to protect ascorbic acid from hydrolysis and oxidation throughout its shelf life.

Ascorbic acid is used in formulation, because it is a potent antioxidant and cofactor. It helps prevent oxidative stress. It accumulates in phagocytic cells such as neutrophils and affects chemotaxis, phagocytosis, formation of reactive oxygen species. It plays a supporting role in defense against pathogens. Ascorbic acid supports both cellular defense and the immune system.

The present invention provides a novel composition of ibuprofen, pseudoephedrine and ascorbic acid as defined by the claims which overcomes the above described problems in prior art and have additive advantages over them.

It is found when the weight ratio of active ingredients (ibuprofen, pseudoephedrine and ascorbic acid) and total tablet weight is between a specific intervals mentioned above paragraph, synergestic effect observed and it also provides an optimum formulation design for this combination pharmaceutical product.

The present invention provides a pharmaceutical composition comprising ibuprofen, pseudoephedrine and ascorbic acid to support immune system of human body.

The present invention provides a pharmaceutical composition comprising ibuprofen, pseudoephedrine and ascorbic acid to provide antioxidant activity for human body.

The present invention provides pharmaceutical composition comprising ibuprofen, pseudoephedrine and ascorbic acid and relevant excipients, characterized by i) to control / program the release of the active ingredients according to well-designed tablet formation, and ii) a smart and well-designed manufacturing process.

The present invention shows well physical properties depends on its stability characteristics in appropriate excipients. It shows good properties to provide basic physical stability.

In preferred embodiment, present invention provides a pharmaceutical composition comprising: pseudoephedrine, ibuprofen and ascorbic acid. In particular the present invention relates to bilayer coated tablet formulations of three active ingredients.

In a particular embodiment, pseudoephedrine or acceptable salts, esters or isomers thereof is used in pharmaceutical composition. In one embodiment, pseudoephedrine is used in the form of hydrochloride and hydrobromide salts or optionally mixtures thereof. In an embodiment, the process of preparing the stable pharmaceutical composition comprises steps of preparing a first layer comprising ibuprofen and pseudoephedrine or salt, solvate, enantiomer thereof, the second layer comprising ascorbic acid followed by compressing of bilayer tablet and coating by a protective layer.

In one embodiment, pharmaceutical composition and its formulation process involve avoiding chemical interaction of ibuprofen and pseudoephedrine with ascorbic acid, using pharmaceutically acceptable formulation technique and excipients in the dosage form.

In one embodiment, pharmaceutical composition having a first layer comprising ibuprofen and pseudoephedrine, being present in the free state or in the form of a salt, and being intimately mixed in the composition; and a second layer comprising ascorbic acid not being intimately mixed with the first layer.

In a further embodiment, the process of preparing a stable pharmaceutical composition comprising:

(a) preparing a first portion comprising granulation of ibuprofen with relevant excipients, followed by mixing of pseudoephedrine HCI with relevant excipients same or different from the excipients used with ibuprofen;

(b) optionally, granulation of ibuprofen and pseudoephedrine followed sieving;

(c) preparing a second portion comprising ascorbic acid and relevant excipients;

(d) compressing the two portions as a bilayer form of a tablet;

(e) optionally, coating a protective layer over the bilayer tablet prepared in step (d).

A layered tablet is a tablet which is made up of two or more distinct cores of granulation compressed together with the individual layers lying one on top of another. In one embodiment this formulation discloses a bilayer pharmaceutical compressed tablet capable of liberating two or more drugs at different or same release rates.

In one embodiment, the barrier layer may be formed by any method, including compression, molding, dipping, or spray coating.

An object of the present invention is to provide a pharmaceutical composition in oral dosage form as a bilayer tablet which provides immediate release of a ibuprofen/pseudoephedrine combination and again immediate release of a ascorbic acid drug that exhibits acceptable bioavailability of each compound.

An additional object of the invention is to provide a pharmaceutical composition in bilayer tablet form of high integrity consisting of an immediate release form of two layers. By this way, chemical interaction of ascorbic acid with other active ingredients can be eliminated. Because ascorbic acid is incompatible with ibuprofen and pseudoephedrine.

In one embodiment, pharmaceutical compositions of the present invention, the active ingredients are generally formulated in dosage units containing from 100 to 600 mg of ibuprofen and 20 to 60 mg of pseudoephedrine and 300 to 1000 mg of ascorbic acid per unit dosage.

In one embodiment, pharmaceutical compositions of the present invention, it comprises 200 to 600 mg of ibuprofen, 30 to 60 mg of pseudoephedrine and 300 to 1000 mg of ascorbic acid per unit dose.

Another object of the present invention is a pharmaceutical composition comprising 200 mg of ibuprofen and 30 mg of pseudoephedrine and 300 mg of ascorbic acid.

Another object of the present invention is a pharmaceutical composition comprising 400 mg of ibuprofen and 30 mg of pseudoephedrine and 300 mg of ascorbic acid.

Another object of the present invention is a pharmaceutical composition comprising 600 mg of ibuprofen and 30 mg of pseudoephedrine and 300 mg of ascorbic acid.

Another object of the present invention is a pharmaceutical composition comprising 200 mg of ibuprofen and 60 mg of pseudoephedrine and 300 mg of ascorbic acid.

Another object of the present invention is a pharmaceutical composition comprising 400 mg of ibuprofen and 60 mg of pseudoephedrine and 300 mg of ascorbic acid.

Another object of the present invention is a pharmaceutical composition comprising 600 mg of ibuprofen and 60 mg of pseudoephedrine and 300 mg of ascorbic acid.

In one embodiment, pharmaceutical composition of the present invention may further comprise diluents, binders, suspending agents, disintegrants, stabilizing agents, adsorbents, surfactants, lubricants, disinfectants, glidants, flavoring agents, sweeteners and other pharmaceutical additives or excipients.

Binders can be selected from the group, but are not limited to, methylcellulose, sodium carboxymethycellulose, calcium carboxymethycellulose, ethyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone (Povidon), gelatine, polyvinyl alcohol, compressible sugar, liquid glucose, dextrates, dextrin, dextrose, maltodextrin, magnesium aluminium silicate, polymethacrylates, sorbitol and other materials known to one of ordinary skill in the art. A preferred binder is polyvinylpyrrolidone. A mixture of binders may also be used.

Diluents can be selected from the group, but are not limited to, calcium hydrogen phosphate calcium carbonate, calcium phosphate, calcium sulphate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, maltodextrin, mannitol, microcrystalline cellulose, potassium chloride, powdered cellulose, pregelatinised starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc, tribasic calcium phosphate, and xylitol or mixture thereof. A preferred diluent is calcium hydrogen phosphate and/or microcrystalline cellulose.

Disintegrants can be selected from the group, but are not limited to, alginic acid, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, microcrystalline cellulose, methyl cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidones, polacrilin potassium, starch, pregelatinised starch, sodium alginate, hydroxypropyl starch and other materials known to one of ordinary skill in the art. The combination of above-mentioned disintegrants can also be used. The preferred disintegrants are croscarmellose sodium and microcrystalline cellulose.

Lubricants can be selected from the group, but are not limited to, vegetable oils, such as hydrogenated vegetable oil or hydrogenated castor oil, polyethylene glycols; stearic acid; derivatives of stearic acid, such as magnesium stearate, sodium stearate, calcium stearate, zinc stearate, glyceryl monostearate, glyceryl palmitostearate and sodium stearyl fumarate; mineral salts, such as talc; and polyvinyl alcohols, microcrystalline cellulose, sodium lauryl sulfate, silica, colloidal silica, cornstarch, calcium silicate, magnesium silicate, silicon hydrogel and other materials known to one of ordinary skill in the art. The preferred lubricant is talc and hydrogenated castor oil.

Glidants can be selected from the group, but are not limited to, colloidal silicon dioxide, colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, magnesium trisilicate, amorphous silica, colloidal silicon, silicon hydrogel, powdered cellulose, silicon dioxide, talc, tribasic calcium phosphate and other materials known to one of ordinary skill in the art. The preferred glidant is talc and hydrogenated castor oil.

Dispersing agents or dispersants can be selected from the group, but are not limited to, colloidal silicon dioxide, talc, magnesium stearate and titanium dioxide and other materials known to one of ordinary skill in the art.

Stabilizing agent can be selected from the group, but are not limited to, consisting of polysorbates, cellulose derivatives such as hydroxylpropylcellulose, hydroxylpropylmethylcellulose, poloxamers, carbomers, silicon dioxide, sodium carboxymethyl cellulose, polyvinylpyrrolidone, polyoxyethylene castor oil derivatives, polyethylene glycols, polyoxyethylene stearates, mono and diglycerides, colloidal silicon dioxide, sodium dodecylsulfate, magnesium aluminum silicate, triethanolamine, stearic acid, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, short and medium chain alcohols, polyvinyl alcohol and combinations thereof.

Surfactants can be selected from the group, but are not limited to, also polyoxyethylene hardened castor oil, glyceryl monostearate, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polyoxyethylene -polyoxypropylene block copolymers, polysorbates 80, sodium laurylsulfate, macrogols, sucrose esters of fatty acids and other materials known to one of ordinary skill in the art.

In the present invention, tablet consists of two layers wherein one layer is consisting ibuprofen/pseudoephedrine combination and the other layer is consisting ascorbic acid, resulting in a bilayer tablet. The components of the pharmaceutical composition according to the present invention are brought together into a bilayer tablet for oral administration as shown in example 1. The following example is understood to be illustrative only. Example 1: Bilayer tablet composition of Ibuprofen/pseudoephedrine/ascorbic acid

First Layer:

Mixture of ibuprofen, calcium hydrogen phosphate and croscarmellose sodium mixture is granulated by addition of separately prepared isopropyl alcohol, povidone and talc mixture and let it to dry.

Colloidal silicon dioxide and microcrystalline cellulose are added to dried mixture and mixed.

The remained parts of colloidal silicon dioxide, microcystalline cellulose and pseudoephedrine hydrochloride is mixed separately and added to final mixture.

First layer mixture is prepared after addition of croscarmellose sodium, talc and oil to the final mixture.

Second layer mixture is prepared separately by mixing ascorbic acid, microcrystalline cellulose, colloidal silicon dioxide and oil.

Separately prepared two parts are then compressed according to spesifications to form a bilayer tablet. The tablets are finally coated.

Claims

1. A pharmaceutical composition as bilayer tablet comprising ibuprofen, pseudoephedrine HCI and ascorbic acid characterized in that; a) First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of ibuprofen is between 3: 10 to 9: 10 (w/w) by the weight of the first layer, b) First layer comprises ibuprofen, pseudoephedrine HCI and relevant excipients, wherein the weight ratio of pseudoephedrine is between 1:25 to 5:25 (w/w) by the weight of the first layer, c) Second layer comprises ascorbic acid and relevant excipients, wherein the weight ratio of ascorbic acid is between 7:10 to 10:10 (w/w) by the weight of the second layer.

2. A pharmaceutical composition according to claim 1, the weight ratio of ibuprofen is between 3: 10 to 9: 10 (w/w) by weight of the first layer.

3. A pharmaceutical composition according to claim 1, the weight ratio of pseudoephedrine is between 1:25 to 5:25 (w/w) by weight of the first layer.

4. A pharmaceutical composition according to claim 1, the weight ratio of ascorbic acid is between 7:10 to 10:10 (w/w) by weight of the second layer.

5. A pharmaceutical composition according to any preceding claims, wherein bilayer tablet is prepared by the steps; a. Mixture of ibuprofen, calcium hydrogen phosphate and croscarmellose sodium mixture is granulated by addition of separately prepared isopropyl alcohol, povidone and talc mixture, b. Colloidal silicon dioxide and microcrystalline cellulose are added to mixture and mixed, c. Colloidal silicon dioxide, microcystalline cellulose and pseudoephedrine hydrochloride is mixed separately and added to final mixture, d. The remained parts of colloidal silicon dioxide, microcystalline cellulose and pseudoephedrine hydrochloride is mixed separately and added to final mixture, e. First layer mixture is prepared after addition of croscarmellose sodium, talc and oil to the final mixture, f. Mixture is prepared separately by mixing ascorbic acid, microcrystalline cellulose, colloidal silicon dioxide and oil for the second layer, g. Separately prepared two parts are then compressed according to spesifications to form a bilayer tablet, h. The tablets are finally coated.

6. A pharmaceutical composition according to claim 1, characterized in that it comprises 200 to 600 mg of ibuprofen, 30 to 60 mg of pseudoephedrine and 300 to 1000 mg of ascorbic acid per unit dose.

7. A pharmaceutical composition according to claim 1, wherein the composition is a film coated tablet composition.